A replicating single-cycle adenovirus vaccine against Ebola virus

Stephanie S. Anguiano-Zarate, William E. Matchett, Pramod N. Nehete, Jagannadha K. Sastry, Andrea Marzi, Michael A. Barry

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although a replication-competent Ad (RC-Ad) vaccine might generate a level of protection approximating that of rVSV, this infectious vector would also risk causing adenovirus disease. We recently described a “single-cycle” adenovirus (SC-Ad) vector that amplifies antigen genes like RC-Ad, but that avoids the risk of adenovirus infection. Here we have tested an SC-Ad6 vector expressing the glycoprotein (GP) from a 2014 EBOV strain in mice, hamsters, and rhesus macaques. We show that SC-Ad6-EBOV GP induces a high level of serum antibodies in all species and mediates significant protection against pseudo-challenge with rVSV-EBOV expressing luciferase in mice and hamsters. These data suggest that SC-Ad6-EBOV GP may be useful during future EBOV outbreaks.

Original languageEnglish (US)
Pages (from-to)1883-1889
Number of pages7
JournalJournal of Infectious Diseases
Issue number12
StatePublished - Nov 5 2018


  • Adenovirus
  • Animal models
  • Ebola virus
  • Single cycle
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'A replicating single-cycle adenovirus vaccine against Ebola virus'. Together they form a unique fingerprint.

Cite this